title: Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
abstract: BACKGROUND
  Neoadjuvant chemotherapy (NACT) is used in breast cancer to evaluate the response to treatment. We examined the usefulness of breast magnetic resonance imaging (MRI) in the evaluation of tumor response after NACT.
  
  
  METHODS
  Breast MRIs of 87 women with MRI after NACT were reviewed. The Spearman coefficient was used for estimating the correlation between MRI and pathologic tumor sizes (ypTs).
  
  
  RESULTS
  The median age was 50 years (range 25 to 83 years). The median MRI size was 1.25 cm (range 0 to 10 cm). The median ypT was 1.20 cm (range 0 to 10.4 cm). The Spearman coefficient between MRI and ypT was .78 (95% confidence interval, .67 to .85; P < .0001). MRI was found to have a positive predictive value of 92% and a negative predictive value of 64% for residual in-breast disease. The sensitivity and specificity of MRI were 86% and 77%, respectively.
  
  
  CONCLUSIONS
  MRI correlates well with the final pathology and can be a useful modality to predict residual disease after NACT and aid in surgical planning.
authors.affiliation: Department of Women's Oncology, Comprehensive Breast Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.
authors.forename: Mindy
authors.initials: M
authors.lastname: Williams
authors.forename: Jennifer
authors.initials: J
authors.lastname: Eatrides
authors.forename: Jongphil
authors.initials: J
authors.lastname: Kim
authors.forename: Harpreet
authors.initials: H
authors.lastname: Talwar
authors.forename: Nicole
authors.initials: N
authors.lastname: Esposito
authors.forename: Margaret
authors.initials: M
authors.lastname: Szabunio
authors.forename: Roohi
authors.initials: R
authors.lastname: Ismail-Khan
authors.forename: John
authors.initials: J
authors.lastname: Kiluk
authors.forename: Marie
authors.initials: M
authors.lastname: Lee
authors.forename: Christine
authors.initials: C
authors.lastname: Laronga
authors.forename: Nazanin
authors.initials: N
authors.lastname: Khakpour
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D002278:Carcinoma in Situ / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018275:Carcinoma, Lobular / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008408:Mastectomy; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D064726:Triple Negative Breast Neoplasms / Q000473:pathology / Q000628:therapy
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Breast cancer; Magnetic resonance imaging; Neoadjuvant chemotherapy